Drug Discovery Targeting Nicotinic Acetylcholine Receptors for Hearing Loss
International Journal of Molecular Sciences · 18.04.2026 · 27 (8) · 3614
DOI: 10.3390/ijms27083614 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.04.2026. Verfasst von Jordan Oman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA. Hauptthemen laut MEDLINE: Receptors, Nicotinic, Hearing Loss, Drug Discovery. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences of the National Institutes of Health, Biomedical and Pharmaceutical Sciences, L.S. Skaggs College of Pharmacy, Idaho State University.
Abstract (Originalsprache)
Hearing loss is detrimental to human health, and currently, more than 1.5 billion people are affected by hearing loss. Active military personnel and construction workers are examples of individuals in the workplace who are exposed to loud noise and are at serious risk of hearing loss. While there is currently no therapy for hearing loss, evidence supports investigating the enhancement of the Medial Olivocochlear (MOC) system, an efferent pathway for hearing that serves as a gain-control for hearing loss protection. Selectively modulating the α9α10 nicotinic acetylcholine receptor (nAChRs) found within this pathway is promising for the development of a new drug class. In this review article, we present the most current findings related to the therapeutic targeting of α9α10 nAChRs for hearing loss. We discuss the loss- or gain-of-function of the receptor, evaluate the known modulators of the receptor, examine their clinical relevance, and discuss their chemical and physical properties. Investigation of this novel pathway may aid in the development of a therapeutic for hearing loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA.
- Department of Pathobiology, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 02155, USA.
ORCID-Profile: Jordan Oman, Pooja Sapkota, Sameena Mateen, Srinath Pashikanti
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences of the National Institutes of Health
- Biomedical and Pharmaceutical Sciences, L.S. Skaggs College of Pharmacy, Idaho State University
Zitieren
APA
Oman, J., Sapkota, P., Mateen, S., Schulte, M., & Pashikanti, S. (2026). Drug Discovery Targeting Nicotinic Acetylcholine Receptors for Hearing Loss. International Journal of Molecular Sciences, 27(8), 3614. https://doi.org/10.3390/ijms27083614
Vancouver
Oman J, Sapkota P, Mateen S, Schulte M, Pashikanti S. Drug Discovery Targeting Nicotinic Acetylcholine Receptors for Hearing Loss. International Journal of Molecular Sciences. 2026;27(8):3614. doi:10.3390/ijms27083614
BibTeX
@article{Oman2026,
author = {Oman, Jordan and Sapkota, Pooja and Mateen, Sameena and Schulte, Marvin and Pashikanti, Srinath},
title = {Drug Discovery Targeting Nicotinic Acetylcholine Receptors for Hearing Loss},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3614},
doi = {10.3390/ijms27083614}
}
EUVIMED